• Also Known As:
  • Hemoglobinopathy
  • Hemoglobin Variants
  • Hemoglobin S
  • Sickle Cell Disease
  • Hemoglobin C Disease
  • Hemoglobin E Disease
  • Thalassemia
  • Hemoglobin Barts
  • Hereditary Persistence of Fetal Hemoglobin
  • HPFH
Medically Reviewed by Expert Board

This page was fact checked by our expert Medical Review Board for accuracy and objectivity. Read more about our editorial policy and review process.

This article was
last modified The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.

What are Hemoglobin abnormalities?

A hemoglobin abnormality is a variant form of hemoglobin that is often inherited and may cause a blood disorder (hemoglobinopathy).

Hemoglobin is the iron-containing protein compound within red blood cells that carries oxygen throughout the body. It is made up of heme, which is the iron-containing portion, and globin chains, which are proteins. The globin protein consists of chains of amino acids, the “building blocks” of proteins. There are several different types of globin chains, named alpha, beta, delta, and gamma. Normal hemoglobin types include:

  • Hemoglobin A (Hb A): makes up about 95%-98% of hemoglobin found in adults; it contains two alpha (α) chains and two beta (β) protein chains.
  • Hemoglobin A2 (Hb A2 ): makes up about 2%-3% of hemoglobin found in adults; it has two alpha (α) and two delta (δ) protein chains.
  • Hemoglobin F (Hb F, fetal hemoglobin): makes up to 1%-2% of hemoglobin found in adults; it has two alpha (α) and two gamma (γ) protein chains. It is the primary hemoglobin produced by the fetus during pregnancy; its production usually falls shortly after birth and reaches adult level within 1-2 years.

Genetic changes (mutations) in the globin genes cause alterations in the globin protein, resulting in structurally altered hemoglobin, such as hemoglobin S, which causes sickle cell, or a decrease in globin chain production (thalassemia). In thalassemia, the reduced production of one of the globin chains upsets the balance of alpha to beta chains and causes abnormal hemoglobin to form (alpha thalassemia) or causes an increase of minor hemoglobin components, such as Hb A2 or Hb F (beta thalassemia).

Four genes code for the alpha globin chains, and two genes (each) code for the beta, delta, and gamma globin chains. (For general information on genetic testing, see The Universe of Genetic Testing.) Mutations may occur in either the alpha or beta globin genes. The most common alpha-chain-related condition is alpha thalassemia. The severity of this condition depends on the number of genes affected. (See Thalassemia for more information.)

Mutations in the beta gene are mostly inherited in an autosomal recessive fashion. This means that the person must have two altered gene copies, one from each parent, to have a hemoglobin variant-related disease. If one normal beta gene and one abnormal beta gene are inherited, the person is heterozygous for the abnormal hemoglobin, known as a carrier. The abnormal gene can be passed on to any children, but it generally does not cause symptoms or significant health concerns in the carrier.

If two abnormal beta genes of the same type are inherited, the person is homozygous. The person would produce the associated hemoglobin variant and may have some associated symptoms and potential for complications. The severity of the condition depends on the genetic mutation and varies from person to person. A copy of the abnormal beta gene would be passed on to any children.

If two abnormal beta genes of different types are inherited, the person is “doubly heterozygous” or “compound heterozygous.” The affected person would typically have symptoms related to one or both of the hemoglobin variants that he or she produces. One of the abnormal beta genes would be passed on to children.

Red blood cells containing abnormal hemoglobin may not carry oxygen efficiently and may be broken down by the body sooner than usual (a shortened survival), resulting in hemolytic anemia. Several hundred hemoglobin variants have been documented, but only a few are common and clinically significant. Some of the most common hemoglobin variants include hemoglobin S, the primary hemoglobin in people with sickle cell disease that causes the red blood cell to become misshapen (sickle), decreasing the cell’s survival; hemoglobin C, which can cause a minor amount of hemolytic anemia; and hemoglobin E, which may cause no symptoms or generally mild symptoms.


About Hemoglobin Abnormalities

Hemoglobin variants

Several hundred abnormal forms of hemoglobin (variants) have been identified, but only a few are common and clinically significant.

Common hemoglobin variants

  • Hemoglobin S: this is the primary hemoglobin in people with sickle cell disease (also known as sickle cell anemia). Approximately 1 in 375 African American babies are born with sickle cell disease, and about 100,000 Americans live with the disorder, according to the Centers for Disease Control and Prevention. Those with Hb S disease have two abnormal beta chains and two normal alpha chains. The presence of hemoglobin S causes the red blood cell to deform and assume a sickle shape when exposed to decreased amounts of oxygen (such as might happen when someone exercises or has infection in the lungs). Sickled red blood cells are rigid and can block small blood vessels, causing pain, impaired circulation, and decreased oxygen delivery, as well as shortened red cell survival. A single beta (βS) copy (known as sickle cell trait, which is present in approximately 8% of African Americans) typically does not cause significant symptoms unless it is combined with another hemoglobin mutation, such as that causing Hb C or beta thalassemia.
  • Hemoglobin C: about 2-3% of African Americans in the United States are heterozygotes for hemoglobin C (have one copy, known as hemoglobin C trait) and are often asymptomatic. Hemoglobin C disease (seen in homozygotes, those with two copies) is rare (0.02% of African Americans) and relatively mild. It usually causes a minor amount of hemolytic anemia and a mild to moderate enlargement of the spleen.
  • Hemoglobin E: Hemoglobin E is one of the most common beta chain hemoglobin variants in the world. It is very prevalent in Southeast Asia, especially in Cambodia, Laos, and Thailand, and in individuals of Southeast Asian descent. People who are homozygous for Hb E (have two copies of βE) generally have a mild hemolytic anemia, microcytic red blood cells, and a mild enlargement of the spleen. A single copy of the hemoglobin E gene does not cause symptoms unless it is combined with another mutation, such as the one for beta thalassemia trait.

Less common hemoglobin variants

There are many other variants. Some are silent – causing no signs or symptoms – while others affect the functionality and/or stability of the hemoglobin molecule. Examples of other variants include: Hemoglobin D, Hemoglobin G, Hemoglobin J, Hemoglobin M, and Hemoglobin Constant Spring caused by a mutation in the alpha globin gene that results in an abnormally long alpha (α) chain and an unstable hemoglobin molecule. Additional examples include:

  • Hemoglobin F: Hb F is the primary hemoglobin produced by the fetus, and its role is to transport oxygen efficiently in a low oxygen environment. Production of Hb F decreases sharply after birth and reaches adult levels by 1-2 years of age. Hb F may be elevated in several congenital disorders. Levels can be normal to significantly increased in beta thalassemia and are frequently increased in individuals with sickle cell anemia and in sickle cell-beta thalassemia. Individuals with sickle cell disease and increased Hb F often have a milder disease, as the F hemoglobin inhibits sickling of the red cells. Hb F levels are also increased in a rare condition called hereditary persistence of fetal hemoglobin (HPFH). This is a group of inherited disorders in which Hb F levels are increased without the signs or clinical features of thalassemia. Different ethnic groups have different mutations causing HPFH. Hb F can also be increased in some acquired conditions involving impaired red blood cell production. Some leukemias and other myeloproliferative neoplasms are also associated with mild elevation in Hb F.
  • Hemoglobin H: Hb H is an abnormal hemoglobin that occurs in some cases of alpha thalassemia. It is composed of four beta (β) globin chains and is produced due to a severe shortage of alpha (α) chains. Although each of the beta (β) globin chains is normal, the tetramer of 4 beta chains does not function normally. It has an increased affinity for oxygen, holding onto it instead of releasing it to the tissues and cells. Hemoglobin H is also associated with significant breakdown of red blood cells (hemolysis) as it is unstable and tends to form solid structures within red blood cells. Serious medical problems are not common in people with hemoglobin H disease, though they often have anemia.
  • Hemoglobin Barts: Hb Barts develops in fetuses with alpha thalassemia. It is formed of four gamma (γ) protein chains when there is a shortage of alpha chains, in a manner similar to the formation of Hemoglobin H. If a small amount of Hb Barts is detected, it usually disappears shortly after birth due to dwindling gamma chain production. These children have one or two alpha gene deletions and are silent carriers or have the alpha thalassemia trait. If a child has a large amount of Hb Barts, he or she usually has hemoglobin H disease and a three-gene deletion. Fetuses with four-gene deletions have hydrops fetalis and usually do not survive without blood transfusions and bone marrow transplants.

A person can also inherit two different abnormal genes, one from each parent. This is known as being compound heterozygous or doubly heterozygous. Several different clinically significant combinations are listed below.

  • Hemoglobin SC disease: inheritance of one beta S gene and one beta C gene results in Hemoglobin SC disease. These individuals have a mild hemolytic anemia and moderate enlargement of the spleen. Persons with Hb SC disease may develop the same vaso-occulsive (blood vessel-blocking) complications as seen in sickle cell anemia, but most cases are less severe.
  • Sickle Cell – Hemoglobin D disease: individuals with sickle cell – Hb D disease have inherited one copy of hemoglobin S and one of hemoglobin D-Los Angeles (or D-Punjab) genes. These people may have occasional sickle crises and moderate hemolytic anemia.
  • Hemoglobin E – beta thalassemia: individuals who are doubly heterozygous for hemoglobin E and beta thalassemia have an anemia that can vary in severity, from mild (or asymptomatic) to severe, dependent on the beta thalassemia mutation(s) present.
  • Hemoglobin S – beta thalassemia: sickle cell – beta thalassemia varies in severity, depending on the beta thalassemia mutation inherited. Some mutations result in decreased beta globin production (beta+) while others completely eliminate it (beta0). Sickle cell – beta+ thalassemia tends to be less severe than sickle cell – beta0 thalassemia. People with sickle cell – beta0 thalassemia tend to have more irreversibly sickled cells, more frequent vaso-occlusive problems, and more severe anemia than those with sickle cell – beta+ thalassemia. It is often difficult to distinguish between sickle cell disease and sickle cell – beta0 thalassemia.

Signs and Symptoms

Signs and symptoms associated with hemoglobin variants can vary in type and severity depending on the variant present and whether an individual has one variant or a combination. Some are the result of an increase in the breakdown (hemolysis) of red blood cells and a shortened RBC survival, leading to anemia. Some examples include:

  • Weakness, fatigue
  • Lack of energy
  • Jaundice
  • Pale skin (pallor)

Some serious signs and symptoms include:

  • Episodes of severe pain
  • Shortness of breath
  • Enlarged spleen
  • Growth problems in children
  • Upper abdomen pain (due to stone formation in gallbladder)


Testing for hemoglobin abnormalities (variants) is done:

  • To screen for common and clinically significant hemoglobin variants in newborns. In all states, this has become a standard part of newborn screening. Infants with variants such as Hb S can benefit from early detection and treatment.
  • As part of prenatal screening, on high-risk women including those with an ethnic background associated with a higher prevalence of hemoglobin variants (such as those of African descent) and those with affected family members. Screening may also be done in conjunction with genetic counseling prior to pregnancy to determine possible carrier status of potential parents.
  • To identify variants in asymptomatic parents with an affected child.
  • To identify hemoglobin variants in those with symptoms of unexplained anemia, with red blood cells (RBCs) that are small and/or paler than normal (microcytosis and hypochromia). It may also be ordered as part of an anemia investigation, or when someone has signs and symptoms associated with hemoglobin variants.

Laboratory tests

Laboratory testing for hemoglobin variants is an exploration of the “normalness” of an individual’s red blood cells, an evaluation of the hemoglobin inside the RBCs, and/or an analysis of relevant gene mutations. Each test provides a piece of the puzzle, giving the clinician important information about the hemoglobins that may be present. Testing typically includes:

  • CBC (complete blood count): The CBC is a snapshot of the cells circulating in the blood. Among other things, the CBC will tell the doctor how many red blood cells are present, how much hemoglobin is in them, and give the doctor an evaluation of the average size of the red blood cells present. Mean corpuscular volume (MCV) is a measurement of the size of the red blood cells. A low MCV is often the first indication of thalassemia. If the MCV is low and iron-deficiency has been ruled out, the person may be a carrier of the thalassemia trait or have a hemoglobin variant that results in smaller than normal RBCs (for example, Hb E).
  • Blood smear (also called a peripheral smear): In this test, a trained laboratorian looks under the microscope at a thin layer of blood on a slide treated with a special stain. The number and type of white blood cells, red blood cells, and platelets can be evaluated to see if they are normal and mature. With a hemoglobinopathy, the red blood cells may be:
    • Smaller than normal (microcytic)
    • Paler than normal (hypochromic)
    • Varying in size (anisocytosis) and shape (poikilocytosis, e.g., sickle-shaped cells)
    • Having a nucleus (nucleated red blood cell, not normal in a mature RBC) or crystal (e.g., C crystal)
    • Having uneven hemoglobin distribution (producing “target cells” that look like a bull’s-eye under the microscope).

    The greater the percentage of abnormal-looking red blood cells, the greater the likelihood of an underlying disorder.

  • Hemoglobinopathy evaluation: These tests identify the type, and measure the relative amount, of the different types of hemoglobin present in an individual’s red blood cells. Most of the common variants can be identified using one of these tests or a combination. The relative amounts of any variant hemoglobin detected can help diagnose combinations of hemoglobin variants and thalassemia (compound heterozygotes).
  • Genetic testing: These tests are used to investigate deletions and mutations in the alpha and beta globin-producing genes. Family studies can be done to evaluate carrier status and the types of mutations present in other family members. Genetic testing is not routinely done but can be used to help confirm hemoglobin variants, thalassemia, and to determine carrier status.


Hemoglobin variants are rarely cured. The main goals in treating hemoglobin variants include relieving pain, minimizing complications and organ damage, and preventing infections. Children with sickle cell disease should have regular childhood vaccinations and influenza vaccination.

Treatment during a sickle cell crisis may involve hospitalization and supportive care, including drinking lots of fluids and taking pain medication. Sometimes blood transfusions are needed to treat severe anemia. Antibiotics are needed if sickle crisis is triggered by infection (e.g., pneumonia).

Individuals with hemoglobin variants can minimize crises by avoiding or managing situations likely to trigger episodes. These situations include overexertion, dehydration, extreme temperatures, altitude changes, smoking, and stress.

Drugs that increase hemoglobin F are available. These drugs (e.g., hydroxyurea) relieve some symptoms, but research into safer and more effective therapy continues. L-glutamine has been approved for use to reduce severe complications of sickle cell anemia. Bone marrow or stem cells transplants from a family member with normal hemoglobin are known to cure sickle cell disease. These treatments are risky and has severe side effects, so they remain rare. Gene therapy to correct the mutated gene is beginning to show promise in small trials, but it will require much more research before it is considered for widespread use.

For more information on treatments, see the links listed in Related Content: Elsewhere on the Web section below.

View Sources

Sources Used in Current Review

What is hemoglobin H disease? Cooley’s Anemia. Available online at http://cooleysanemia.org/updates/HemHEnglish.pdf. Accessed May 2017.

(2011 August). Kohne E. Hemoglobinopathies. Dtsch Arztebl Int. 2011 August; 108(31-32): 532–540. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163784/. Accessed May 2017.

(2014 July 14). Stem cell transplant reverses sickle cell disease in adults. NIH Research Matters. Available online at https://www.nih.gov/news-events/nih-research-matters/stem-cell-transplant-reverses-sickle-cell-disease-adults. Accessed May 2017.

(©2015). Hemoglobinopathies: Current practices for screening, confirmation and follow-up. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/ncbddd/sicklecell/documents/nbs_hemoglobinopathy-testing_122015.pdf. Accessed May 2017.

(2016 August 31). Sickle cell disease, data and statistics. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed May 2017.

Maakaron J. (2016 October 3). Sickle cell anemia. Medscape. Available online at http://emedicine.medscape.com/article/205926-overview. Accessed May 2017.

(©2017). Alpha thalassemia trait. St. Jude Children’s Research Hospital. Available online at https://www.stjude.org/treatment/disease/sickle-cell-disease/diagnosing-sickle-cell/alpha-thalassemia-trait.html. Accessed May 2017.

Braunstein, E. M. (2017 January). Hemoglobin S-C disease. Merck Manual, Professional Version. Available online at http://www.merckmanuals.com/professional/hematology-and-oncology/anemias-caused-by-hemolysis/hemoglobin-s-c-disease. Accessed May 2017.

Mitton, B.A. (2017 January 19). Hemoglobin C Disease. Medscape. Available online at http://emedicine.medscape.com/article/200853-overview. Accessed May 2017.

Cheerva A. (2017 February 27). Alpha Thalassemia. Medscape. Available online at http://emedicine.medscape.com/article/206397-overview. Accessed May 2017.

Coghlan, A. (2017 March 1). Gene therapy ‘cures’ boy of blood disease that affects millions. New Scientist. Available online at https://www.newscientist.com/article/mg23331154-800-gene-therapy-breakthrough/. Accessed May 2017.

(2017 May). Hemoglobinopathies. ARUP Consult. Available online at https://arupconsult.com/content/hemoglobinopathies. Accessed May 2017.

(©1995-2017). Hemoglobin F, red cell distribution, blood. Mayo Medical Laboratories. Available online at http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/8270. Accessed May 2017.

Sources Used in Previous Reviews

Harmening D. Clinical Hematology and Fundamentals of Hemostasis. Fifth Edition, F.A. Davis Company, Philadelphia, 2009, Chapters 11 and 12.

Henry’s Clinical Diagnosis and Management by Laboratory Methods. 21st ed. McPherson R, Pincus M, eds. Philadelphia, PA: Saunders Elsevier: 2007, Pp 520-522.

Clarke, W. and Dufour, D. R., editors (2006). Contemporary Practice in Clinical Chemistry. AACC Press, Washington, DC Pp 213-224.

(February 8, 2012) MedlinePlus Medical Encyclopedia. Hemoglobin electrophoresis. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/003639.htm. Accessed December 2012.

(October 5, 2011) Cheerva A. Alpha Thalassemia. Medscape Review article. Available online at http://emedicine.medscape.com/article/206397-overview. Accessed December 2012.

(January 3, 2012) Maakaron J. Sickle Cell Anemia. Medscape Review article. Available online at http://emedicine.medscape.com/article/205926-overview. Accessed December 2012.

(May 16, 2012) Carter S. Hemoglobin C Disease. Medscape Reference Article. Available online at http://emedicine.medscape.com/article/200853-overview. Accessed December 2012.

(©2012 University of Rochester) Health Encyclopedia. Sickle Cell Disease. Available online at http://www.urmc.rochester.edu/Encyclopedia/Content.aspx?ContentTypeID=85&ContentID=P00101. Accessed December 2012.

(©2012 University of Rochester) Health Encyclopedia. Alpha Thalassemia. Available online at http://www.urmc.rochester.edu/Encyclopedia/Content.aspx?ContentTypeID=85&ContentID=P00074. Accessed December 2012.

(©2012 University of Rochester) Health Encyclopedia. Beta Thalassemia. Available online at http://www.urmc.rochester.edu/Encyclopedia/Content.aspx?ContentTypeID=85&ContentID=P00081. Accessed December 2012.

(©2012 Mayo Medical Laboratories) Test Catalog. Thalassemia and Hemoglobinopathy Evaluation. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/84158 through. Accessed December 2012.

(Published online August 2011) Kohne E. Hemoglobinopathies. Dtsch Arztebl Int. 2011 August; 108(31-32): 532–540. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163784/. Accessed December 2012.

©2013 St. Jude Children’s Research Hospital. Hemoglobin C Trait. Available online at http://www.stjude.org/stjude/v/index.jsp?vgnextoid=f1b0db6324d6f110VgnVCM1000001e0215acRCRD. Accessed February 2013.

(September 16, 2011) Centers for Disease Control and Prevention. Sickle Cell Disease, Data and Statistics. Available online at http://www.cdc.gov/NCBDDD/sicklecell/data.html. Accessed February 2013.